Search results
Results From The WOW.Com Content Network
Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires' disease. [3]
Rifampin rapidly kills fast-dividing bacilli strains as well as "persisters" cells, which remain biologically inactive for long periods of time that allow them to evade antibiotic activity. [7] In addition, rifabutin and rifapentine have both been used against tuberculosis acquired in HIV-positive patients.
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
Rifapentine, sold under the brand name Priftin, is an antibiotic used in the treatment of tuberculosis. [2] In active tuberculosis it is used together with other antituberculosis medications. [2]
The hope of a fixed-dose combination pill is to increase the likelihood that people will take all of three medications. [5] Also, if people forget to take one or two of their drugs, they might not then develop resistance to the remaining drugs.
Isoniazid/rifampicin, also known as isoniazid/rifampin, is a medication used to treat tuberculosis. [1] It is a fixed dose combination of isoniazid and rifampicin (rifampin). [1] It is used together with other antituberculosis medication. [1] It is taken by mouth. [1] It is on the World Health Organization's List of Essential Medicines. [2]
Regular service generally entails stopping at the border, changing from a Vietnamese metre-gauge train to a Chinese standard-gauge train, and continuing on to Nanning. [26] The Yunnan–Vietnam Railway will form the Chinese part of the Singapore–Kunming Rail Link, which is expected to be completed in 2015. [27] Cambodia and Laos
This page was last edited on 5 November 2023, at 03:42 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.